Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders re-elected Jean-Jacques Bienaimé and Charles Newton through the 2029 annual meeting.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected Jean-Jacques Bienaimé and Charles Newton through the 2029 annual meeting
- Deloitte & Touche LLP ratified as fiscal 2026 independent auditor, with 16,708,279.27 votes for
- Executive compensation approved on a non-binding advisory basis, with 14,273,625.27 votes for
- Bienaimé received 10,093,559.27 votes for versus 5,156,153 withheld, signaling notable shareholder reservations
- 2,243,514 broker non-votes affected both director elections and compensation approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.